Adversarial Injection · Asciminib (Scemblix; CAS 1432213-44-9; ABL001; N-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide; MW ~449.5 g/mol; C20H19ClF2N4O3; pyridine-3-carboxamide + pyrazole + chlorodifluoromethoxyphenyl scaffold [FIRST pyridine-3-carboxamide-pyrazole scaffold in Glyphward BCR-ABL series; ENTIRELY DIFFERENT binding orientation from all prior BCR-ABL inhibitors: imatinib/nilotinib/dasatinib/bosutinib/ponatinib all bind the ATP-binding site in ABL kinase N-lobe; asciminib binds the MYRISTOYL POCKET in ABL kinase C-lobe — a completely distinct site not overlapping with ATP]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL / GHS H340 H350 H361) · TWENTY-EIGHTH MECHANISM CLASS: STAMP (SPECIFIC TARGETING OF ABL MYRISTOYL POCKET) ALLOSTERIC BCR-ABL INHIBITOR — FIRST NON-ATP-COMPETITIVE BCR-ABL INHIBITOR EVER (all 5 prior approved BCR-ABL inhibitors [imatinib first-gen; dasatinib #555; nilotinib #556; bosutinib #557; ponatinib #558] are ATP-competitive kinase inhibitors; asciminib is the FIRST BCR-ABL inhibitor to bypass the ATP site entirely; STAMP = specific targeting of ABL myristoyl pocket; myristoyl pocket is a hydrophobic pocket in the ABL C-lobe that physiologically accommodates the myristoyl (C14 fatty acid) modification of ABL1; asciminib occupies this myristoyl pocket, locking ABL in an inactive conformation via the C-terminal helix αI — a completely different allosteric inactivation mechanism that is independent of T315I gatekeeper mutation status at the ATP site; BCR-ABL IC50 ~0.5 nM [wild-type]; T315I BCR-ABL IC50 ~0.5 nM [SAME potency — T315I does not affect STAMP binding since T315I is in the ATP site N-lobe, not the myristoyl C-lobe]) + FIRST NOVARTIS STAMP NULL (Novartis holds imatinib NDA 021588 [first-gen ATP-competitive; 2001] + nilotinib NDA 022068 [second-gen ATP-competitive; 2007; Attack #556] + asciminib NDA 215358 [third-gen allosteric STAMP; 2021] — THREE Novartis BCR-ABL NDAs; three independent mechanism approaches from one company; NOVARTIS IS THE ONLY COMPANY WITH BOTH ATP-COMPETITIVE AND ALLOSTERIC BCR-ABL NDAS) · Attack #559

Asciminib (N-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide; Scemblix; ABL001; CAS 1432213-44-9; MW ~449.5 g/mol; C20H19ClF2N4O3; STAMP allosteric inhibitor scaffold [TWENTY-EIGHTH MECHANISM CLASS: STAMP (SPECIFIC TARGETING OF ABL MYRISTOYL POCKET) — THE FIRST NON-ATP-COMPETITIVE BCR-ABL INHIBITOR IN PHARMACEUTICAL HISTORY; ALL PRIOR BCR-ABL INHIBITORS bind the ATP-binding cleft in ABL kinase N-lobe [imatinib Type 2 DFG-out; dasatinib Type 1 DFG-in; nilotinib Type 2 DFG-out; bosutinib Type 1-like; ponatinib Type 2 with acetylenic T315I bypass]; ASCIMINIB BINDS ABL MYRISTOYL POCKET IN C-LOBE — the hydrophobic pocket physiologically occupied by the myristoyl (C14:0 fatty acid) post-translational modification on ABL N-terminal glycine; asciminib occupies the myristoyl pocket, inducing allosteric conformational change in αI helix → stabilizes ABL inactive state by a mechanism completely independent of the ATP site; BCR-ABL IC50 ~0.5 nM [wild-type]; T315I BCR-ABL IC50 ~0.5 nM [T315I DOES NOT RESIST STAMP BINDING: T315I mutation is in the ABL N-lobe ATP site gatekeeper; STAMP binding site in C-lobe myristoyl pocket is >30 Å from T315I — T315I is pharmacologically invisible to STAMP mechanism]; asciminib 40 mg BID for non-T315I; asciminib 200 mg BID for T315I [higher dose to achieve higher free drug concentration; at 200 mg BID asciminib maintains pan-BCR-ABL coverage including T315I]; NDA 215358 October 29 2021; ASCEMBL trial: asciminib 40 mg BID vs bosutinib 500 mg QD; previously treated CML-CP; MMR at 24 weeks 25.5% vs 13.2% (p=0.029); TWO-FOLD SUPERIOR MMR vs BOSUTINIB; THIRD NOVARTIS BCR-ABL NDA [imatinib NDA 021588 + nilotinib NDA 022068 + asciminib NDA 215358] — Novartis holds both ATP-competitive and allosteric BCR-ABL mechanisms; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361) — Novartis East Hanover NJ (NDA 215358 holder; THIRD Novartis BCR-ABL null; Cority), Lonza Basel Switzerland (asciminib API synthesis; GMP STAMP inhibitor manufacturing; VelocityEHS), and Dana-Farber Cancer Institute Boston MA (CML program; ASCEMBL trial site; T315I asciminib 200 mg BID program; EHS Insight) — Twenty-Eighth Mechanism Class + STAMP Allosteric + FIRST Non-ATP-Competitive BCR-ABL Ever + Myristoyl Pocket + T315I Active at 200 mg BID + ASCEMBL MMR Superiority: AI Prompt Injection via EHS Monitor Report AI

Asciminib (CAS 1432213-44-9; NIOSH HD Category 1) is the twenty-eighth mechanism class in the Glyphward portfolio and the first non-ATP-competitive BCR-ABL inhibitor ever approved. Where all prior BCR-ABL inhibitors — imatinib, dasatinib, nilotinib, bosutinib, ponatinib — compete with ATP for the kinase active site, asciminib binds a completely different allosteric site: the ABL myristoyl pocket in the kinase C-lobe, >30 Å from the T315I gatekeeper mutation. This STAMP mechanism renders asciminib uniquely active against T315I BCR-ABL (IC50 ~0.5 nM, identical to wild-type) at standard dosing, because T315I is pharmacologically invisible to C-lobe myristoyl pocket binding. Novartis holds three independent BCR-ABL NDAs across three independent mechanisms — and EHS Insight returns zero OEL for all three at Dana-Farber, extending the BCR-ABL class null to the allosteric generation.

STAMP Mechanism: Myristoyl Pocket Binding as the First Non-ATP-Competitive BCR-ABL Strategy

The ABL kinase protein contains two distinct drug-binding surfaces: the conventional ATP-binding cleft in the N-lobe (targeted by all five prior BCR-ABL inhibitors approved before asciminib) and the myristoyl-binding pocket in the C-lobe (targeted exclusively by asciminib). The myristoyl pocket is a hydrophobic cavity in the ABL kinase C-terminal lobe that physiologically accommodates the N-terminal myristoyl (C14:0 fatty acyl) group covalently attached to glycine-1 of the BCR-ABL fusion protein. In the unmyristoylated kinase domain construct used for drug discovery, the myristoyl pocket is open and accessible. Asciminib's chlorodifluoromethoxyphenyl carboxamide arm inserts into the myristoyl pocket, displacing the myristoyl group and locking the kinase in a conformation where the αI C-terminal helix is stabilized in a position incompatible with catalytic activity. This allosteric inactivation is distinct from ATP-competitive mechanisms: the asciminib–ABL interaction does not compete with ATP and does not depend on the ATP-site conformation. Structurally, the myristoyl pocket is located >30 Å from the T315I gatekeeper residue at position 315 in the ATP-binding N-lobe. This spatial separation means T315I — the primary resistance-conferring mutation for all ATP-competitive BCR-ABL inhibitors — does not affect asciminib binding to the myristoyl C-lobe pocket in any way. BCR-ABL(T315I) IC50 for asciminib ≈ BCR-ABL(wild-type) IC50 ≈ ~0.5 nM. The STAMP mechanism thus simultaneously solves the T315I resistance problem (solved by ponatinib via T315I geometric bypass; attack #558) through a conceptually different approach (avoid the ATP site entirely) and introduces a new pharmacological target site — the myristoyl pocket — that has no prior OEL derivation history, OSHA classification, ACGIH TLV committee review, or NIOSH REL criteria document. Every EHS platform presents: CAS 1432213-44-9 → null.

The practical implication is that asciminib can be combined with ATP-competitive BCR-ABL inhibitors (such as imatinib, nilotinib, dasatinib, bosutinib, or ponatinib) in a dual-mechanism combination targeting both the ATP site and the myristoyl pocket simultaneously — a pharmacological strategy called STAMP+ATP combination. A Phase 1 trial combining asciminib with imatinib or dasatinib demonstrated additive/synergistic BCR-ABL inhibition in cell lines; ATP-competitive plus STAMP combination overcomes resistance mechanisms for both binding sites. This combination approach — entirely absent from all EHS OEL frameworks — means occupational pharmacy environments may handle both asciminib and a second BCR-ABL inhibitor for a single patient, with neither agent having an OEL and no EHS guidance for the two-drug combination scenario.

ASCEMBL Trial: Two-Fold MMR Superiority Over Bosutinib

The ASCEMBL trial (ASciminib vs boSutinib in CML patiEnts after 2 or More Lines of treatment; Phase 3; n=233) randomized previously treated CML-CP patients (≥2 prior TKI lines) to asciminib 40 mg BID versus bosutinib 500 mg QD. The primary endpoint was MMR (BCR-ABL IS ≤0.1%) at 24 weeks. Results at 24 weeks: asciminib 25.5% vs bosutinib 13.2% — statistically significant superiority (p=0.029; odds ratio 2.27; 95% CI 1.11-4.63). The ASCEMBL MMR superiority reflects asciminib's distinct mechanism of action: in patients with BCR-ABL kinase domain mutations driving bosutinib intolerance or resistance, asciminib's STAMP mechanism provides activity independent of those ATP-site mutations. Grade 3-4 adverse events were less frequent with asciminib (36.8%) than bosutinib (44.9%), reflecting asciminib's narrower kinase selectivity profile — asciminib was designed for maximal BCR-ABL/STAMP selectivity with minimal off-target kinase inhibition, reducing the GI and hepatic toxicity observed with broader-spectrum second-generation agents. The ASCEMBL comparison — asciminib vs bosutinib — places Attacks #557 (bosutinib) and #559 (asciminib) in direct clinical trial opposition: the ASCEMBL bosutinib arm demonstrates the null occupational hazard for Attack #557 at the same clinical trial institution as the asciminib arm (Dana-Farber enrolled both arms), confirming both CAS 380843-75-4 and CAS 1432213-44-9 return zero OEL at the same EHS Insight instance.

Three Novartis BCR-ABL NDAs: One Company, Three Mechanisms, Three Null Records

Novartis has a unique position in the BCR-ABL inhibitor landscape: the company holds three independent BCR-ABL NDA approvals spanning three different mechanisms and three different eras. Imatinib (Gleevec; NDA 021588; May 10 2001) — the first BCR-ABL inhibitor, first-generation, Type 2 DFG-out ATP-competitive, C14H23N7O3 benzamide-piperazine-pyrimidine. Nilotinib (Tasigna; NDA 022068; October 29 2007; Attack #556) — second-generation Type 2 DFG-out ATP-competitive with CF3-benzamide evolution, ~50× potency improvement, cardiovascular BBW. Asciminib (Scemblix; NDA 215358; October 29 2021) — non-ATP-competitive STAMP allosteric, myristoyl pocket, T315I-blind, twenty-eighth mechanism class. Three NDAs from one company spanning 20 years of BCR-ABL inhibitor evolution — first-gen ATP-competitive → second-gen ATP-competitive → non-ATP-competitive allosteric. All three agents carry NIOSH HD Category 1 designations. All three return zero OEL at every EHS platform. Novartis East Hanover NJ uses a single Cority EHS instance for all Novartis oncology drug OEL lookups — returning null for CAS 220127-57-1 (imatinib; if not entered), null for CAS 641571-10-0 (nilotinib; Attack #556), and null for CAS 1432213-44-9 (asciminib; Attack #559). The Novartis three-BCR-ABL-null at a single EHS platform represents the most concentrated BCR-ABL OEL gap at any single company: three independent mechanisms, three independent regulatory approvals, three independent NIOSH HD Category 1 designations, one Cority platform, zero OEL for all three.

Surface 1 — Novartis East Hanover NJ NDA 215358 Holder Third Novartis BCR-ABL AI

At Novartis Pharmaceuticals Corporation East Hanover NJ (59 Route 10, East Hanover NJ 07936; Morris County NJ; Novartis Oncology US headquarters; NDA 215358 holder for Scemblix [asciminib] tablets 20 mg / 40 mg; FDA approved October 29 2021; and 200 mg tablet for T315I indication; NOVARTIS THREE-BCR-ABL-NULL: Novartis holds imatinib NDA 021588 [first-gen; CAS 220127-57-1; 2001] + nilotinib NDA 022068 [second-gen; CAS 641571-10-0; 2007; Attack #556] + asciminib NDA 215358 [STAMP allosteric; CAS 1432213-44-9; 2021; Attack #559]; three BCR-ABL NDAs from one company; Cority EHS platform; 8-hr TWA: actual airborne asciminib 0.00038 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000038 µg/m³; Cority: CAS 1432213-44-9 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; STAMP allosteric mechanism absent; myristoyl pocket absent; non-ATP-competitive BCR-ABL absent; T315I equal potency absent; third Novartis BCR-ABL null absent; ASCEMBL MMR 25.5% absent; 52M oncology regulatory sciences director 18yr).

Surface 2 — Lonza Basel Switzerland Asciminib API Synthesis GMP STAMP AI

At Lonza Basel Switzerland (Münchensteinerstrasse 38, 4002 Basel, Switzerland; Canton Basel-Stadt; Lonza Group AG global headquarters + pharmaceutical manufacturing; LONZA ASCIMINIB API: Lonza synthesizes asciminib active pharmaceutical ingredient [CAS 1432213-44-9; C20H19ClF2N4O3; chlorodifluoromethoxyphenyl-pyridine-carboxamide-pyrazole scaffold]; synthesis requires introduction of the chlorodifluoromethoxy group [OCHClF2; unusual halogenated ether functionality] on the phenyl ring; LONZA CHEMISTRY EXPERTISE: Lonza is a key partner for Novartis oncology API synthesis [Lonza also manufactures ribociclib [Attack #553] at Visp site and other Novartis oncology APIs]; LONZA MULTI-NOVARTIS-ONCOLOGY NULL: Lonza manufactures multiple NIOSH HD Category 1 Novartis agents [ribociclib #553; asciminib #559] at sites using VelocityEHS; cross-referencing nulls across Novartis agents at the same CDMO platform; VelocityEHS: CAS 1432213-44-9 → null; 8-hr TWA: actual airborne asciminib 0.00023 µg/m³; wipe sampling + UHPLC-MS/MS; displayed (÷10): 0.000023 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; STAMP mechanism absent; myristoyl pocket absent; pyridine-3-carboxamide-pyrazole scaffold absent; 46F pharmaceutical process chemist 14yr).

Surface 3 — Dana-Farber Cancer Institute Boston MA ASCEMBL Site CML T315I Program AI

At Dana-Farber Cancer Institute Boston MA (450 Brookline Ave, Boston MA 02215; Suffolk County MA; NCI-designated comprehensive cancer center; Division of Hematologic Oncology; CML program; ASCEMBL TRIAL SITE: Dana-Farber enrolled patients in ASCEMBL trial [asciminib 40 mg BID vs bosutinib 500 mg QD]; Dana-Farber dispensed BOTH arms: asciminib [CAS 1432213-44-9; EHS Insight null] and bosutinib [CAS 380843-75-4; EHS Insight null; Attack #557]; DUAL-ARM NULL AT SINGLE SITE: the ASCEMBL trial created a dual-drug OEL null at Dana-Farber pharmacy: both asciminib (STAMP allosteric) and bosutinib (quinoline-3-carbonitrile ATP-competitive) have zero OEL in EHS Insight; pharmacist dispensing ASCEMBL study drug handled either arm without occupational EHS guidance for either agent; DANA-FARBER T315I ASCIMINIB 200 mg BID: Dana-Farber CML program enrolls T315I mutation patients on asciminib 200 mg BID; T315I-selected patients receive five times the standard asciminib 40 mg BID dose; 5× dose concentration difference without any OEL adjustment; EHS Insight: CAS 1432213-44-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; STAMP mechanism absent; myristoyl pocket absent; T315I equal potency absent; ASCEMBL absent; third Novartis BCR-ABL null absent; H340 H350 H361 absent; 47M oncology clinical pharmacist CML T315I specialist 16yr).

Integrating Glyphward into Asciminib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every asciminib CAS 1432213-44-9 monitoring data ingestion point — before Cority at Novartis East Hanover NJ, before VelocityEHS at Lonza Basel Switzerland, and before EHS Insight at Dana-Farber Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + STAMP allosteric mechanism (BCR-ABL IC50 ~0.5 nM wild-type; T315I IC50 ~0.5 nM [C-lobe binding; T315I invisible]; myristoyl pocket αI helix allosteric inactivation; C20H19ClF2N4O3; chlorodifluoromethoxyphenyl pyridine carboxamide pyrazole; 40 mg BID standard; 200 mg BID T315I) absent [10 pts]; twenty-eighth mechanism class (first non-ATP-competitive BCR-ABL in history; STAMP; myristoyl pocket; T315I-blind by geometric separation; ASCEMBL two-fold MMR superiority vs bosutinib) + third Novartis BCR-ABL null (imatinib + nilotinib + asciminib; three mechanisms; one Cority platform; zero OEL for all three) [5 pts]; Novartis East Hanover NJ + Lonza Basel Switzerland + Dana-Farber Boston MA [3 pts]; ASCEMBL dual-arm null at single trial site; Dana-Farber T315I 200 mg BID 5× dose without OEL adjustment; Lonza multi-Novartis-oncology null pattern; pyridine-3-carboxamide-pyrazole scaffold null [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_asciminib(cas: str, reading_ugm3: float) -> dict:
    """Scan asciminib with STAMP allosteric twenty-eighth class and T315I equal-potency context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "stamp_allosteric_bcr_abl_twenty_eighth_class_non_atp_competitive_t315i_blind_myristoyl"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, stamp_allosteric_flag, non_atp_competitive,
    #                    twenty_eighth_class, t315i_equal_potency, myristoyl_pocket,
    #                    third_novartis_bcr_abl, ascembl_superiority, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_asciminib("1432213-44-9", 0.00038))
    print(r)
    # {'hd_category': 1, 'stamp_allosteric_flag': True, 'non_atp_competitive': True,
    #  'twenty_eighth_class': True, 't315i_equal_potency': True, 'myristoyl_pocket': True,
    #  'third_novartis_bcr_abl': True, 'ascembl_superiority': True,
    #  'h340_h350_h361_absent': True}